Physician profile
Norman Wang
NPI 1790713907
$5,631.57
in general payments reported to CMS, 2019-2025
25 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $338 · 2021: $1,404 · 2022: $956 · 2023: $200 · 2024: $522 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,197.02 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Eisai INC. | $779.16 | 2019-2021 | |
| Sk Life Science, INC. | $752.22 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $469.17 | 2019-2022 | |
| Neuropace, INC. | $446.80 | 2020-2025 | |
| Abbvie INC. | $420.82 | 2021-2023 | Qulipta |
| Ucb, INC. | $301.86 | 2019-2025 | Fintepla |
| Jazz Pharmaceuticals INC. | $290.68 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $214.03 | 2019-2024 | Ultomiris |
| Neurelis, INC. | $189.36 | 2021-2024 | Valtoco |
| Greenwich Biosciences, INC. | $125.01 | 2019-2021 | |
| Medtronic, INC. | $109.34 | 2023 | Sensight |
| Monteris Medical Corporation | $102.63 | 2021 | |
| Neurocrine Biosciences, INC. | $46.07 | 2020-2021 | |
| Lundbeck LLC | $40.21 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zogenix INC. | $30.98 | 2021 | |
| Relievant Medsystems, INC. | $22.18 | 2020 | |
| Amgen INC. | $19.45 | 2019 | |
| Merz North America, INC. | $19.36 | 2019 | |
| Aquestive Therapeutics, INC. | $15.93 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.75 | 2022 | |
| Lilly USA, LLC | $13.34 | 2019 | |
| Allergan, INC. | $11.20 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.